Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus TRAMADOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus TRAMADOL HYDROCHLORIDE.
METHADOSE vs TRAMADOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Tramadol hydrochloride is a centrally acting opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission in the central nervous system.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
50-100 mg orally every 4-6 hours as needed for pain, not to exceed 400 mg/day (100 mg for immediate-release).
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
5-6 hours (parent drug); 7-9 hours (M1 active metabolite). In renal impairment, half-life prolonged up to 11 hours (parent) and 17 hours (M1).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Primarily renal (90% total clearance, 30% as unchanged drug, 60% as metabolites); fecal (~10%); biliary minor.
Category C
Category D/X
Opioid Agonist
Opioid Agonist